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Abstract. Deregulation of mitotic spindle genes has been 
reported to contribute to the development and progression 
of malignant tumours. The aim of the present study was to 
explore the association between the expression profiles of 
Aurora kinases (AURKA, AURKB and AURKC), cytoskel-
eton-associated protein 5 (CKAP5), discs large-associated 
protein 5 (DLGAP5), kinesin-like protein 11 (KIF11), micro-
tubule nucleation factor (TPX2), monopolar spindle 1 kinase 
(TTK), and β-tubulins (TUBB) and (TUBB3) genes and clini-
copathological characteristics in human non-small cell lung 
carcinoma (NSCLC). Reverse transcription-quantitative poly-
merase chain reaction‑based RNA gene expression profiles of 
132 NSCLC and 44 adjacent wild-type tissues were generated, 
and Cox's proportional hazard regression was used to examine 
associations. With the exception of AURKC, all genes exhib-
ited increased expression in NSCLC tissues. Of the 10 genes 
examined, only AURKA was significantly associated with 
prognosis in NSCLC. Multivariate Cox's regression analysis 
demonstrated that AURKA mRNA expression [hazard ratio 
(HR), 1.81; 95% confidence interval (CI), 1.16‑2.84; P=0.009], 
age (HR, 1.03; 95% CI, 1.00‑1.06; P=0.020), pathological 
tumour stage 2 (HR, 2.43; 95% CI, 1.16‑5.10; P=0.019) and 
involvement of distal nodes (pathological node stage 2) (HR, 
3.14; 95% CI, 1.24‑7.99; P=0.016) were independent predictors 
of poor prognosis in patients with NSCLC. Poor prognosis of 
patients with increased AURKA expression suggests that those 
patients may benefit from surrogate therapy with AURKA 
inhibitors.
Introduction
Lung cancer is the most common cause of cancer-associated 
mortality in the UK for both males and females (1), and 
>1/5 patients with cancer succumb to this malignancy world-
wide (2). Non-small cell lung carcinoma (NSCLC) accounts 
for 80-85% of all cases of lung cancer, and develops through 
the accumulation of molecular alterations, which may serve as 
prognostic biomarkers for NSCLC outcome (3).
Mitotic spindle formation and the spindle checkpoint are 
critical for the maintenance of cell division and chromosome 
segregation (4). A number of mitotic spindle-associated 
proteins have been implicated in multiple malignancies, 
including lung cancer (5,6). Overexpression and gene ampli-
fication have been reported to contribute to the development 
and progression of malignant tumours for a number of 
mitotic spindle genes, including those involved in centro-
some maturation [e.g., Aurora kinase (AURK)A, microtubule 
nucleation factor TPX2 (TPX2) and kinesin-like protein 11 
(KIF11)] (7,8), microtubule formation [e.g., AURKA, cyto-
skeleton-associated protein 5 (CKAP5), tubulin β (TUBB) 
and TUBB3] (9-11), and chromosomal alignment and segrega-
tion [e.g., AURKA, AURKB, AURKC, discs large-associated 
protein 5 (DLGAP5) and TTK protein kinase (TTK)] (12-14). 
AURKA serves a central role in recruiting other mitotic 
spindle members (5). A number of previous studies conducted 
in lung cancer have investigated the prognostic value of 
various of the aforementioned genes, including TPX2 (15), 
AURKA (16-18) and AURKB (18-21); however, the prognostic 
value of AURKA and AURKB remains a matter of debate. 
No information on the potential prognostic significance in 
human NSCLC has yet been provided for DLGAP5, CKAP5 
or TTK.
Personalised medicine relies on the utilisation of gene 
profiling (including expression, mutation and methylation) 
in combination with clinicopathological characteristics to 
provide an optimal management plan for the patient. Therefore, 
it is necessary to expand our efforts in investigating the asso-
ciation of particular molecular profiles with patient outcomes. 
The aim of the present study was to acquire a comprehen-
sive expression profile of mitotic spindle-associated genes 
(AURKA, AURKB, AURKC, CKAP5, DLGAP5, KIF11, TPX2, 
TTK, TUBB and TUBB3) in NSCLC and to investigate the 
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potential associations with clinicopathological characteristics 
and patient survival rates.
Materials and methods
Patients and samples. The present study was undertaken within 
the context of the Liverpool Lung Project (22). Appropriate 
ethical approval from the Liverpool Research Ethics 
Committee, ref 157/97, was obtained and all patients provided 
written informed consent. A total of 132 frozen surgical tumour 
samples, collected between January 1999 and December 2005 
at Liverpool Heart and Chest Hospital (Liverpool, UK), were 
available from patients with primary NSCLC, 56 from adeno-
carcinoma (AdC) and 76 from squamous cell carcinoma of the 
lung (SqCCL). In addition, 44 paired non‑tumour surgical lung 
samples (20 from patients with AdC and 24 from patients with 
SqCCL) were analysed. The median age of the patients was 
67 years (range, 45-82 years); 56 of the patients were female 
and 77 were male. The majority of the specimens were of the 
pathological tumour (pT)2 stage (n=101), whereas the pT1 and 
pT3/4 groups comprised 19 and 12 patients, respectively. The 
HBEC‑3KT cell line (23) used as a calibrator was provided by 
Professor John Minna and Professor Adi Gazdar.
RNA extraction and reverse transcription‑quantitative 
polymerase chain reaction (RT‑qPCR). Total RNA was 
extracted from primary lung tumour tissue (ten 20-µm thick 
sections per specimen) using a Direct‑zol™ RNA MiniPrep 
kit (Zymo Research Corp., Irvine, CA, USA), according to 
the manufacturer's protocol. The quality and quantity of RNA 
were determined using a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific, Inc., Wilmington, DE, USA) and 
200 ng RNA was reverse transcribed using a High-Capacity 
cDNA Reverse Transcription kit (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA), according to the manufacturer's 
protocol. Predesigned 6‑carboxyfluorescein‑labelled TaqMan 
Gene Expression Assays (Thermo Fisher Scientific, Inc.) 
were employed, according to the manufacturer's protocol, 
to analyse mRNA expression: AURKA, Hs01582072_m1; 
AURKB, Hs00945858_g1; AURKC, Hs00152930_m1; 
CKAP5, Hs01120723_m1; DLGAP5, Hs00207323_m1, KIF11, 
Hs00189698_m1; TPX2, Hs00201616_m1; TTK, Hs01009870_
m1; TUBB, Hs00962419_g1; and TUBB3, Hs00964962_g1, 
with a 4,7,2'‑trichloro‑7'‑phenyl‑6‑carboxyfluorescein‑labelled 
β-actin (ACTB) TaqMan Gene Expression Assay (cat. 
no. 4326315E; Thermo Fisher Scientific, Inc.) serving as an 
endogenous control. RNA from human bronchial epithelial 
cells (HBEC‑3KT) was used as technical calibrator. Three 
technical replicates were performed for every qPCR assay. 
Thermocycling conditions were 95˚C for 10 min (activation), 
45 cycles of 95˚C for 15 sec (denaturation), 60˚C for 1 min 
(annealing and extension)] on a Life Technologies StepOnePlus 
Real‑Time PCR System. mRNA levels were expressed as 
relative quantification (RQ) values, which were calculated 
as RQ=2-ΔΔCq (24). Quantification cycle (Cq) values were 
determined using StepOne software (version 1.2; Thermo 
Fisher Scientific, Inc.) and normalised to the corresponding 
Cq value for the endogenous control ACTB, generating ΔCq 
values (ΔCq=Cq target‑Cq ACTB). Sample ΔCq values 
were further normalised against an immortalised bronchial 
epithelial cell line HBEC‑3KT (23) calibrator using the 
formula: ΔΔCq=(ΔCq sample-ΔCq HBEC‑3KT).
Statistical analysis. Gene expression in tumour and adjacent 
wild-type tissues were compared using the Wilcoxon non-para-
metric test. The study characteristics were examined using 
descriptive statistics. Categorical variables were compared 
using a χ2 test and continuous variables were examined using 
a Mann‑Whitney U test. Overall survival time was calculated 
from the date of surgery to the date of mortality or last follow-up 
date. Overexpression for a tumour sample was designated as 
>95% reference interval [mean ± (2x standard deviation)] of 
wild‑type tissues. Postoperative univariate survival analysis 
was explored using Kaplan‑Meier estimator curves for all the 
categorical predictors. Tests of equality across strata were also 
conducted to evaluate the suitability of including potential 
predictors in the final multivariate model. For the categorical 
variables, a log-rank test of equality across strata was used, 
and a univariate Cox's proportional hazard regression was used 
to analyse continuous variables to examine the differences in 
survival rate. Variables with P<0.25 in the univariate analysis 
were selected for inclusion in the final multivariate model as 
previously suggested (25). A multivariate Cox's proportional 
hazard model was used to examine the association between 
mRNA expression and other relevant prognostic factors. All 
statistical analyses were performed using IBM® SPSS® statis-
tical software (version 22.0; IBM SPSS, Armonk, NY, USA) 
and Stata® (version 13.1; StataCorp LLC, College Station, 
TX, USA). P<0.05 was considered to indicate a statistically 
significant difference.
Results
Gene expression analysis. RT‑qPCR analysis revealed that, 
with the exception of AURKC, the mRNA expression levels 
of all the genes examined in the present study (AURKA, 
AURKB, AURKC, DLGAP5, CKAP5, KIF11, TPX2, TTK, 
TUBB and TUBB3) were significantly upregulated in NSCLC 
tissues compared with those in wild-type adjacent lung tissues 
(P<0.0001; Fig. 1). Comparison between histology types 
(Fig. 2) revealed that the mRNA expression of seven genes 
was significantly increased in SqCCL compared with that in 
AdC tissues (P<0.001 for AURKA, AURKB, DLGAP5, TPX2, 
TTK and TUBB; P=0.001 for KIF11).
Survival analysis. There was no association between the 
mRNA expression of any of the genes evaluated with age, sex, 
pathological stage or nodal status (Table I). Potential asso-
ciations between the expression level of the target genes and 
overall survival rate were examined. In univariate analysis, 
pathological stage, nodal status and AURKA mRNA expres-
sion were predictors of overall survival rate (Table II). Most 
importantly, multivariate analysis demonstrated that AURKA 
mRNA expression [hazard ratio (HR), 1.81; 95% confidence 
interval (CI) 1.16‑2.84; P=0.009] independently predicts 
poor prognosis in patients with NSCLC upon adjusting for 
age, pT2 and involvement of distal nodes (pathological node 
stage 2) (Table II). This observation was consistent with the 
Kaplan‑Meier estimator curve (Fig. 3). The association with 
prognosis remained significant even when SqCCL and AdC 
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tissues were tested separately (P=0.025 and P=0.029, respec-
tively; Fig. 3).
Discussion
Spindle formation is a key process for cell proliferation (8). 
It is well known that spindle assembly aberrations lead to 
aneuploidy and are extensively involved in the development 
of cancer (26). Thus, it was hypothesised that the expression 
of genes associated with this process may be indicative of the 
aggressiveness of a tumour and therefore may exhibit prog-
nostic value.
In the present study, the mRNA expression of the AURKA, 
AURKB, AURKC, CKAP5, DLGAP5, KIF11, TPX2, TTK, 
TUBB and TUBB3 genes was investigated in a large cohort 
of human NSCLC tissues, and potential associations between 
expression profiles and clinicopathological characteristics, 
including survival rates, were evaluated. All genes, with the 
exception of AURKC, were overexpressed in the malignant 
tissues in comparison with adjacent wild-type tissues. These 
results possibly reflect the requirement for increased mitotic 
spindle genes expression to cope with the increased replication 
rate of cancer cells (27,28). However, the important clinical 
question is whether the overexpression of any of these genes 
is able to confer a selective advantage on cancer cells and 
increase their invasive properties. The results of the present 
study confirm that up‑regulation of mitotic spindle genes is 
a common abnormality in NSCLC and further support a role 
for the maintenance of a tumorigenic phenotype (5,29). The 
results of the present study demonstrated that, of the 10 genes 
examined, only AURKA overexpression was associated with 
poor prognosis, which suggests that this gene has a particular 
contribution to a more aggressive phenotype. It is notable 
that multivariate Cox's regression analysis identified AURKA 
mRNA expression as an independent predictor of poor prog-
nosis in patients with NSCLC.
The overexpression of AURKA in NSCLC has been demon-
strated previously (16,17). Consistent with these previous 
studies, it was observed in the present study that AURKA 
mRNA overexpression was increased in SqCCL compared 
with that in AdC tissue. However, the prognostic value of 
AURKA in lung cancer has not yet been established. In contrast 
to the study of Tang et al (30), the prognostic significance of 
AURKA expression in the present study appears to hold true 
Figure 1. Comparative mRNA expression of the examined genes in NSCLC tissues and adjacent normal tissues. The mRNA expression levels of the genes in 
NSCLC tumours are significantly higher than those in adjacent normal tissues, with the exception of AURKC. P‑values were calculated using a Mann‑Whitney 
U test and adjusted for multiple comparisons by Bonferroni correction. RQ values were calculated using RNA from the non‑tumorigenic immortalised human 
bronchial epithelial cell line HBEC‑3KT as a calibrator. Larger circles represent outlier values (>1.5x interquartile range); smaller circles represent extreme 
values (>3x interquartile range). NSCLC, non‑small cell lung cancer; RQ, relative quantification; AURK, Aurora kinase; DLGAP5, discs large-associated 
protein 5; CKAP5, cytoskeleton-associated protein 5; KIF11, kinesin-like protein 11; TPX2, microtubule nucleation factor TPX2; TTK, TTK protein kinase; 
TUBB, tubulin β.
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for both histological subtypes. There is a lack of consensus 
on this issue, with previous studies debating on the prognostic 
significance of AURKA in SqCCL (17,18). Furthermore, peri-
membrane immunohistochemical staining was demonstrated 
to be a marked predictor of poor prognosis in patients with 
SqCCL, but not in patients with AdC (16), whereas microarray 
data analysis demonstrated that AURKA mRNA overexpres-
sion is associated with poor prognosis in patients with AdC, 
but not in patients with SqCCL (30). The reported differ-
ences are possibly due to dissimilarities in the study design, 
Figure 2. mRNA expression of AURKA, AURKB, AURKC, DLGAP5, CKAP5, KIF11, TPX2, TTK, TUBB and TUBB3 genes in SqCCL and AdC of the lung. 
Comparison between histology types demonstrated that the mRNA expression levels of the AURKA, AURKB, DLGAP5, KIF11, TPX2, TTK and TUBB genes 
in SqCCL tumours are significantly higher than those in AdC tumours. P‑values were calculated using a Mann‑Whitney U test and adjusted for multiple 
comparisons by Bonferroni correction. RQ values were calculated using RNA from the non‑tumorigenic immortalised human bronchial epithelial cell line 
HBEC‑3KT as a calibrator. Larger circles represent outlier values (>1.5x interquartile range); smaller circles represent extreme values (>3x interquartile 
range). AURK, Aurora kinase; DLGAP5, discs large-associated protein 5; CKAP5, cytoskeleton-associated protein 5; KIF11, kinesin-like protein 11; TPX2, 
microtubule nucleation factor TPX2; TTK, TTK protein kinase; TUBB, tubulin β; SqCCL, squamous cell carcinoma of the lung; AdC, adenocarcinoma; RQ, 
relative quantification.
Figure 3. Kaplan‑Meier estimator curves of cumulative survival of patients with NSCLC dichotomised by 95% reference interval of AURKA mRNA expres-
sion in wild‑type tissues. The P‑values were calculated using a log‑rank (Mantel‑Cox) test. Increased AURKA expression (unbroken line) is associated with 
decreased survival time. The correlation between AURKA expression and cumulative survival is significant in AdC and SqCCL. Decreased AURKA expression 
(broken line) is associated with increased survival time. NSCLC, non-small cell lung cancer; AdC, adenocarcinoma; SqCCL, squamous cell carcinoma of the 
lung.
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measurement of AURKA expression and the small study size, 
which decreases statistical significance. It is imperative that a 
large multicentre study is undertaken to determine a definitive 
explanation of these discrepancies.
AURKA overexpression may serve an important role in 
cancer aggressiveness through a range of underlying molec-
ular mechanisms. Elevated levels of AURKA perturb mitotic 
spindle formation and therefore cytokinesis due to centro-
some amplification, leading to chromosomal instability and 
consequently aneuploidy or polyploidy (5,31). AURKA over-
expression also inactivates several tumour-suppressor genes, 
including p53 (32). The association between AURKA overex-
pression and p53 mutation, as well as advanced tumour grade 
and advanced cancer stage, was also reported in patients with 
hepatocellular carcinoma (33), and with clinically aggressive 
disease and decreased survival rates in patients with ovarian 
cancer (34). These AURKA-associated events (the perturbation 
of spindle formation and inactivation of tumour-suppressor 
Table II. Univariate and multivariate Cox's proportional hazard regression analyses of potential predictors of overall survival 
among the study patients.
 Univariate Multivariate
 -------------------------------------------------------------------------------- -----------------------------------------------------------------------------
Covariates HR (95% CI) P‑value HR (95% CI) P‑value
AURKA mRNA 1.79 (1.16‑2.77) 0.009 1.81 (1.16‑2.84) 0.009
Age 1.02 (1.00-1.05) 0.066 1.03 (1.00-1.06) 0.020
Tumour stage    
  1 Reference Reference Reference Reference
  2 2.82 (1.35-5.86) 0.006 2.43 (1.16-5.10) 0.019
  ≥3 3.80 (1.42‑10.15) 0.008 1.39 (0.38‑5.09) 0.623
Nodal status    
  0 Reference Reference Reference Reference
  1 1.62 (1.03-2.55) 0.037 1.45 (0.90-2.34) 0.128
  2 2.55 (1.35-4.84) 0.004 3.14 (1.24-7.99) 0.016
HR, hazard ratio; CI, confidence interval; AURK, Aurora kinase.
Table I. Clinicopathological characteristics of the study patients in association with AURKA mRNA expression profile.
Clinicopathological Total number of High expression of Low expression of 
characteristic patients (%) 124 (100) Aurora‑A mRNA (n=59) Aurora‑A mRNA (n=65) P‑value
Mean age, years 66.5 (8.5) 65.9 (8.5) 67.5 (8.5) 0.223a
(standard deviation)
Gender    0.180b
  Male 70 (56.5) 37 (52.9) 33 (47.1) 
  Female 54 (43.5) 22 (40.7) 32 (59.3) 
Histology    <0.001b
  Adenocarcinoma  52 (41.9) 13 (25.0) 39 (75.0) 
  Squamous cell carcinoma 72 (58.1) 46 (63.9) 26 (36.1) 
Tumour stage    0.513b
  1 19 (15.3) 7 (36.8) 12 (63.2) 
  2 91 (73.3) 45 (49.5) 46 (50.6) 
  ≥3 12 (9.6) 7 (58.3) 5 (41.7) 
Nodal status    0.975b
  0 68 (54.8) 32 (47.1) 36 (52.9) 
  1 38 (30.6) 18 (47.4) 20 (52.6) 
  2 18 (14.6) 9 (50.0) 9 (50.0) 
aMann‑Whitney U test; bχ2 test. AURK, Aurora kinase.
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genes by elevated AURKA expression) may explain the asso-
ciation identified between up‑regulated AURKA expression 
and poor outcome of patients with NSCLC. Nonetheless, the 
hypothesis that up-regulated AURKA expression contributes 
to a poor survival outcome in lung cancer has been debated, 
presumably because NSCLC represents a set of heterogeneous 
malignancies, with various outcomes, even among those with 
the same clinicopathological features (35). The results of the 
present study provide evidence to support the prognostic role 
of AURKA expression in patients with NSCLC and highlight 
the requirement for a large multicentre clinical study which 
will take into consideration further parameters, including 
therapeutic regimens. Most importantly, the results of the 
present study suggest that NSCLC patients may benefit from 
therapy with AURKA inhibitors and this requires validation 
in a prospective clinical study.
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